Association International Extranodal Lymphoma Study Group (IELSG)

5 trials Academic / non-commercial Merged from 2 name variants

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

0 Recruiting

5 Completed trials

9 Countries active

7 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 1 Phase II: 4

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Marginal zone lymphoma 2 Extranodal marginal zone B-cell lymphoma (MALT type) 1 Splenic marginal zone lymphoma 1 Ocular lymphoma 1

Top IMPs

RITUXIMAB 3 ACALABRUTINIB 1 IBRUTINIB 1 TAFASITAMAB 1 ZANUBRUTINIB 1

All trials

5 total

Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients Ended

2023-503755-10-00 Phase III 7 countries RITUXIMAB; ZANUBRUTINIB
Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphoma Ended

2024-514122-23-00 Phase II 2 countries ACALABRUTINIB; TAFASITAMAB
Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas Ended

2023-507886-25-00 Phase II 4 countries IBRUTINIB; RITUXIMAB
THIS IS A CLINICAL STUDY WHICH EVALUATES TREATMENT WITH CHLORAMBUCIL AND RITUXIMAB FOLLOWED BY RITUXIMAB GIVEN UNDER THE SKIN IN PATIENTS W… Ended

2023-507291-52-00 Phase II 2 countries RITUXIMAB
Clinical trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycyclin… Ended

2024-513426-29-00 Phase II 1 country

Showing 1–5 of 5 trials

← All sponsors A–Z